Cerity Partners
CPRX

Cerity Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Cerity Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664K Sell
21,139
-10,804
-34% -$319K ﹤0.01% 2250
2026
Q1 		$791K Sell
31,943
-548
-2% -$13.1K ﹤0.01% 1990
2025
Q4 		$758K Buy
32,491
+236
+0.7% +$5.26K ﹤0.01% 1849
2025
Q3 		$635K Buy
32,255
+3,183
+11% +$65.5K ﹤0.01% 1836
2025
Q2 		$631K Buy
29,072
+231
+0.8% +$5.45K ﹤0.01% 1751
2025
Q1 		$699K Buy
28,841
+2,359
+9% +$53.1K ﹤0.01% 1588
2024
Q4 		$548K Sell
26,482
-2,251
-8% -$48.4K ﹤0.01% 1708
2024
Q3 		$571K Buy
28,733
+6,847
+31% +$127K ﹤0.01% 1706
2024
Q2 		$339K Sell
21,886
-940
-4% -$14.6K ﹤0.01% 1754
2024
Q1 		$364K Buy
22,826
+5,595
+32% +$84.3K ﹤0.01% 1763
2023
Q4 		$290K Buy
17,231
+1,780
+12% +$24.3K ﹤0.01% 1537
2023
Q3 		$181K Buy
+15,451
New +$207K ﹤0.01% 1292
2023
Q2 		– Sell
-554
Closed -$437K – 1702
2023
Q1 		$437K Buy
+554
New +$9.14K ﹤0.01% 1352

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cerity Partners's CPRX Position: Q2 2026 in Review

Cerity Partners reduced its Catalyst Pharmaceutical (CPRX) stake by 34% in Q2 2026, selling an estimated $319K and leaving 21,139 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Cerity Partners first reported a position in CPRX in Q1 2023 and has held it in 13 quarters since. The position peaked at $791K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cerity Partners held 21,139 shares of Catalyst Pharmaceutical worth $664K as of Q2 2026.
  • Cerity Partners sold 10,804 Catalyst Pharmaceutical shares in Q2 2026, an estimated $319K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2250 holding.
  • Cerity Partners first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
  • Cerity Partners's Catalyst Pharmaceutical position peaked at $791K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.